This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Suzuken Co., Ltd.'s Equity Buyback Plan announced on November 10, 2023. CI
Suzuken Co., Ltd.'s Equity Buyback announced on November 10, 2023, has closed with 5,124,900 shares, representing 6.19% for ¥24,999.95 million. CI
Tranche Update on Suzuken Co., Ltd.'s Equity Buyback Plan announced on November 10, 2023. CI
Jefferies Downgrades Suzuken to Hold from Buy, Adjusts Price Target to 5,200 Yen From 5,700 Yen MT
Suzuken Co., Ltd. announces an Equity Buyback for 6,000,000 shares, representing 7.25% for ¥25,000 million. CI
Suzuken Co., Ltd. agreed to acquire a 16.61% stake in Welby Inc. from Digital Garage, Inc. for ¥1.4 billion CI
Suzuken Co., Ltd. authorizes a Buyback Plan. CI
Frontier Field Co., Ltd. announced that it has received funding from Suzuken Co., Ltd., NCB Venture Capital Co., Ltd., Otsuka Pharmaceutical Factory, Inc., SBI Investment Co., Ltd., Yamanashi Chugin Management Consulting Co., Ltd., Investment Arm CI
Suzuken Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Suzuken Co., Ltd.’s Equity Buyback announced on November 11, 2022, has expired. CI
Frontier Field Co., Ltd. announced that it expects to receive funding from Suzuken Co., Ltd., CI
Frontier Field Co., Ltd. announced that it expects to receive funding from Suzuken Co., Ltd. CI
Tranche Update on Suzuken Co., Ltd.'s Equity Buyback Plan announced on November 11, 2022. CI
Suzuken Co., Ltd. announces an Equity Buyback for 5,500,000 shares, representing 6.25% for ¥20,000 million. CI
Suzuken Co., Ltd. authorizes a Buyback Plan. CI
SmartShopping, Inc. announced that it has received ¥1 billion in funding from Suzuken Co., Ltd. CI
SanBio and Suzuken Receive Patent Involving Regenerative Medicines MT
Suzuken Co., Ltd. completed the acquisition of 49% stake in EP-PharmaLine Co., Ltd. from EPS Holdings, Inc. CI
Tranche Update on Suzuken Co., Ltd.'s Equity Buyback Plan announced on May 27, 2021. CI
Suzuken Co., Ltd.'s Equity Buyback announced on May 27, 2021, has expired with 1,292,000 shares, representing 1.45% for ¥4,427.58 million. CI
Suzuken Co., Ltd. agreed to acquire 49% stake in EP-PharmaLine Co., Ltd. from EPS Holdings, Inc. CI
Doctors Co., Ltd. announced that it has received funding from Suzuken Co., Ltd. CI
Doctors Co., Ltd. announced that it expects to receive funding from Suzuken Co., Ltd. CI
SmartShopping, Inc. announced that it has received funding from Suzuken Co., Ltd., M3, Inc. CI
Suzuken Revises Earnings Guidance for the Fiscal Year Ending March 31, 2022 CI
Chart Suzuken Co., Ltd.
More charts
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
4,821 JPY
Average target price
4,840 JPY
Spread / Average Target
+0.39%
Consensus
  1. Stock Market
  2. Equities
  3. 9987 Stock
  4. News Suzuken Co., Ltd.
  5. Jefferies Downgrades Suzuken to Hold from Buy, Adjusts Price Target to 5,200 Yen From 5,700 Yen